UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) 660 White Plains R ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q2 2022 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & CEO Christine Sacco - CFO Conference Call Participants Jon Andersen - William Blair Rupesh Parikh - Oppenheimer Steph Wissink - Jefferies Mitchell Pinheiro - Sturdivant & Co Operator Thank you for standing by, and welcome to the Q2 2022 Prestige Consumer Healthcare, Inc. Earnings Conference Cal ...

N o v e m b e r 4 t h , 2 0 2 1 Second Quarter FY 2022 Results P C H C O N F I D E N T I A L A N D P R O P R I E T A R Y I N F O R M A T I O N Safe Harbor Disclosure 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, adjusted EPS, free cash flow, and organic revenue growth; the Company's ability to perform well in the curren ...

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the unaudited condensed consolidated financial statements and management's analysis of financial performance [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including income, balance sheet, and cash flow data, along with explanatory notes for key accounting policies and events [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) This section details the company's revenues, gross profit, operating income, net income, and diluted EPS for the specified periods Consolidated Statement of Income Highlights (Unaudited) | Metric | Three Months Ended Sep 30, 2021 (In thousands) | Three Months Ended Sep 30, 2020 (In thousands) | Six Months Ended Sep 30, 2021 (In thousands) | Six Months Ended Sep 30, 2020 (In thousands) | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | $276,225 | $237,422 | $545,406 | $466,816 | | **Gross Profit** | $157,712 | $137,661 | $316,724 | $271,529 | | **Operating Income** | $78,558 | $72,903 | $169,900 | $153,022 | | **Net Income** | $45,325 | $44,589 | $103,080 | $88,295 | | **Diluted EPS** | $0.89 | $0.88 | $2.03 | $1.74 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's assets, liabilities, and stockholders' equity at the end of the reporting periods Consolidated Balance Sheet Highlights (Unaudited) | Metric | September 30, 2021 (In thousands) | March 31, 2021 (In thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $304,810 | $269,835 | | **Goodwill** | $578,797 | $578,079 | | **Intangible Assets, net** | $2,689,920 | $2,475,729 | | **Total Assets** | $3,675,818 | $3,429,273 | | **Long-term Debt, net** | $1,592,981 | $1,479,653 | | **Total Liabilities** | $2,214,171 | $2,070,975 | | **Total Stockholders' Equity** | $1,461,647 | $1,358,298 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section outlines the cash inflows and outflows from operating, investing, and financing activities for the reporting periods Consolidated Statement of Cash Flows Highlights (Unaudited) | Metric | Six Months Ended Sep 30, 2021 (In thousands) | Six Months Ended Sep 30, 2020 (In thousands) | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $130,499 | $127,293 | | **Net cash used in investing activities** | ($232,989) | ($11,619) | | **Net cash provided by (used in) financing activities** | $114,184 | ($186,666) | | **Increase (decrease) in cash and cash equivalents** | $10,516 | ($68,157) | - The significant increase in cash used in investing activities was driven by the **$228.9 million** acquisition of Akorn's consumer health business[23](index=23&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations of significant accounting policies, recent acquisitions, debt refinancing, and other material financial events - The company completed the acquisition of consumer health business assets from Akorn on July 1, 2021, for a purchase price of **$228.9 million** in cash. This acquisition added the *TheraTears* brand and other over-the-counter consumer brands to the company's portfolio[33](index=33&type=chunk) - The COVID-19 pandemic has had a mixed impact, with some categories like Women's Health and Oral Care benefiting, while others like Cough & Cold were negatively impacted. However, the pandemic has not had a material negative impact on overall operations, sales, or liquidity to date[26](index=26&type=chunk)[27](index=27&type=chunk) - As of September 30, 2021, total long-term debt stood at **$1.62 billion**. The company refinanced its term loan on July 1, 2021, to fund the Akorn acquisition and extend the maturity date to July 1, 2028[53](index=53&type=chunk)[54](index=54&type=chunk) - The company has significant customer concentration risk, with Walmart accounting for approximately **22.7%** and **21.2%** of gross revenues for the three and six months ended September 30, 2021, respectively[86](index=86&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes the company's financial performance, liquidity, and capital resources, highlighting revenue growth, margin pressures, and the impact of the Akorn acquisition [Results of Operations (Three Months Ended Sep 30, 2021 vs 2020)](index=31&type=section&id=Results%20of%20Operations%20%28Three%20Months%20Ended%20Sep%2030%2C%202021%20vs%202020%29) This section details the company's financial performance for the three months ended September 30, 2021, compared to the prior year, focusing on revenue and expense drivers - Total revenues increased by **16.3%** to **$276.2 million**, driven by a **16.2%** increase in the North American OTC segment and a **17.5%** increase in the International OTC segment[112](index=112&type=chunk) - The North American revenue growth was primarily driven by the Eye & Ear Care category, which included the newly acquired *TheraTears* brand, and recovery in the Cough & Cold and Gastrointestinal categories as COVID-19 restrictions eased[113](index=113&type=chunk) - Gross profit margin decreased slightly from **58.0%** to **57.1%**, primarily due to increased supply chain costs and a **$1.6 million** charge related to the inventory valuation of the acquired Akorn brands[116](index=116&type=chunk) - General and administrative expenses increased from **$20.4 million** to **$32.3 million**, largely due to **$5.1 million** in costs related to the Akorn acquisition[124](index=124&type=chunk) [Results of Operations (Six Months Ended Sep 30, 2021 vs 2020)](index=34&type=section&id=Results%20of%20Operations%20%28Six%20Months%20Ended%20Sep%2030%2C%202021%20vs%202020%29) This section analyzes the company's financial results for the six months ended September 30, 2021, compared to the prior year, focusing on revenue, gross profit, and net interest expense - Total revenues for the six-month period increased by **16.8%** to **$545.4 million**. The North American segment grew **15.7%**, and the International segment grew **29.6%**[131](index=131&type=chunk) - Gross profit increased **16.6%** to **$316.7 million**, with the gross margin remaining relatively stable at **58.1%** compared to **58.2%** in the prior year[135](index=135&type=chunk) - Net interest expense decreased to **$31.4 million** from **$43.2 million**, driven by a lower average cost of borrowing (**4.0%** vs. **5.1%**) and slightly lower average indebtedness[144](index=144&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) This section evaluates the company's cash flow generation, capital allocation, debt structure, and compliance with financial covenants - Net cash provided by operating activities was strong at **$130.5 million** for the six months ended September 30, 2021[149](index=149&type=chunk) - The company used **$228.9 million** for the acquisition of Akorn, which was the primary driver of the **$233.0 million** in net cash used in investing activities[150](index=150&type=chunk) - On July 1, 2021, the company refinanced its term loan, creating a new class of Term B-5 Loans in an aggregate principal amount of **$600.0 million** to fund the Akorn acquisition and extend the maturity to 2028[153](index=153&type=chunk)[154](index=154&type=chunk) - As of September 30, 2021, total outstanding indebtedness was **$1.6 billion**, and the company was in compliance with all debt covenants[152](index=152&type=chunk)[157](index=157&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section details the company's exposure to market risks, including interest rate fluctuations on variable-rate debt and foreign currency exchange rate volatility - A hypothetical **1.0%** increase in interest rates on the company's variable rate debt would adversely impact pre-tax earnings by approximately **$1.1 million** for the quarter[169](index=169&type=chunk) - Approximately **11.8%** of gross revenues for the quarter were denominated in currencies other than the U.S. Dollar, primarily Canadian and Australian Dollars. A hypothetical **10%** adverse change in exchange rates would impact pre-tax income by approximately **$1.8 million** for the quarter[170](index=170&type=chunk)[171](index=171&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that as of September 30, 2021, the company's disclosure controls and procedures were effective[172](index=172&type=chunk) - No changes occurred during the quarter ended September 30, 2021, that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[173](index=173&type=chunk) [PART II. OTHER INFORMATION](index=42&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section provides additional information, including updates on risk factors and a list of exhibits filed with the quarterly report [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) This section confirms no material changes to the risk factors previously disclosed in the Annual Report on Form 10-K for the fiscal year ended March 31, 2021 - The risk factors described in the company's Annual Report on Form 10-K for the year ended March 31, 2021, have not materially changed during the period covered by this quarterly report[174](index=174&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including amendments to credit agreements and required officer certifications - Key exhibits filed include Amendment No. 6 to the Term Loan Credit Agreement and CEO/CFO certifications pursuant to the Securities Exchange Act of 1934[178](index=178&type=chunk)

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2022 Results Conference Call August 5, 2021 8:30 AM ET Company Participants Phil Terpolilli - VP, IR Ron Lombardi - Chairman, President and CEO Christine Sacco - CFO Conference Call Participants Rupesh Parikh - Oppenheimer Jon Andersen - William Blair Steph Wissink - Jefferies Linda Bolton-Weiser - D.A. Davidson Mitch Pinheiro - Sturdivant Anthony Lebiedzinski - Sidoti & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q1 20 ...

First Quarter FY 2022 Results August 5tʰ, 2021 HEALTHCARE O ULTIMATE Safe Harbor Disclosure 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, adjusted EPS, free cash flow, and organic revenue growth, and the related impact of the TheraTears acquistion; the Company's ability to perform well in the currently evolving environm ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Prestige Consumer Healthcare Inc. reported Q1 2022 revenues of **$269.2 million** (**+17.3%**) and net income of **$57.8 million** [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) | Metric | Three Months Ended June 30, 2021 (in thousands) | Three Months Ended June 30, 2020 (in thousands) | | :--- | :--- | :--- | | **Total Revenues** | $269,181 | $229,394 | | **Gross Profit** | $159,012 | $133,868 | | **Operating Income** | $91,342 | $80,119 | | **Net Income** | $57,755 | $43,706 | | **Diluted EPS** | $1.14 | $0.86 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) | Metric | June 30, 2021 (in thousands) | March 31, 2021 (in thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $408,524 | $269,835 | | **Total Assets** | $3,559,114 | $3,429,273 | | **Total Current Liabilities** | $125,046 | $122,138 | | **Long-term Debt, net** | $1,545,352 | $1,479,653 | | **Total Liabilities** | $2,142,867 | $2,070,975 | | **Total Stockholders' Equity** | $1,416,247 | $1,358,298 | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) | Cash Flow Activity | Three Months Ended June 30, 2021 (in thousands) | Three Months Ended June 30, 2020 (in thousands) | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $69,305 | $75,154 | | **Net cash used in investing activities** | ($1,323) | ($2,553) | | **Net cash provided by (used in) financing activities** | $63,650 | ($111,362) | | **Increase (decrease) in cash and cash equivalents** | $131,322 | ($36,819) | | **Cash and cash equivalents - end of period** | $163,624 | $57,941 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - The COVID-19 pandemic caused volatile demand, with categories like Women's Health and Oral Care benefiting, while Cough & Cold was negatively impacted, though Q1 fiscal 2022 saw significant increases in travel-related categories[23](index=23&type=chunk) - As of June 30, 2021, the company had **$1.56 billion** in long-term debt, including senior notes and term loans, with **$85.0 million** outstanding on the ABL Revolver and a remaining borrowing capacity of **$57.1 million**[42](index=42&type=chunk) - On July 1, 2021, the company acquired Akorn's Consumer Health business assets, including the TheraTears brand, for **$230 million** in cash, funded by cash on hand, revolver borrowings, and a term loan refinancing[83](index=83&type=chunk) - On July 1, 2021, the company refinanced its term loan, creating a new class of Term B-5 Loans with an aggregate principal of **$600 million** and extending the maturity date to July 1, 2028[85](index=85&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Q1 2022 revenues grew **17.3%** to **$269.2 million**, driven by OTC segment growth from easing COVID-19 restrictions and improved gross profit margin [Results of Operations](index=26&type=section&id=Results%20of%20Operations) Total Segment Revenues (Three Months Ended June 30, in thousands) | Segment | 2021 Revenue | 2020 Revenue | % Change | | :--- | :--- | :--- | :--- | | **North American OTC Healthcare** | $242,393 | $210,658 | 15.1% | | **International OTC Healthcare** | $26,788 | $18,736 | 43.0% | | **Total Consolidated** | **$269,181** | **$229,394** | **17.3%** | - The North American OTC segment's revenue growth was primarily driven by the Eye & Ear Care (**+57.5%**) and Gastrointestinal (**+41.0%**) categories, benefiting from increased consumer travel as COVID-19 restrictions eased[96](index=96&type=chunk)[97](index=97&type=chunk) - The International OTC segment's revenue growth was mainly attributable to increased sales of Hydralyte in Australia, also due to easing COVID-19 restrictions[98](index=98&type=chunk) - Gross profit as a percentage of total revenues increased to **59.1%** from **58.4%** in the prior-year period, primarily due to a favorable product mix[100](index=100&type=chunk) - Net interest expense decreased to **$15.1 million** from **$21.9 million**, driven by a reduction in average indebtedness (from **$1.7 billion** to **$1.5 billion**) and a lower average cost of borrowing (from **5.1%** to **4.0%**)[109](index=109&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=Liquidity%20and%20Capital%20Resources) Cash Flow Summary (Three Months Ended June 30, in thousands) | Activity | 2021 | 2020 | | :--- | :--- | :--- | | **Operating Activities** | $69,305 | $75,154 | | **Investing Activities** | ($1,323) | ($2,553) | | **Financing Activities** | $63,650 | ($111,362) | - Cash and cash equivalents increased by **$131.3 million** during the quarter to end at **$163.6 million** as of June 30, 2021[112](index=112&type=chunk) - The company borrowed **$85.0 million** under its revolving credit agreement in June 2021 in anticipation of the acquisition of Akorn's Consumer Health business, which was completed on July 1, 2021[115](index=115&type=chunk)[118](index=118&type=chunk) - As of June 30, 2021, the company had **$1.6 billion** of outstanding indebtedness and was in compliance with all debt covenants[116](index=116&type=chunk)[124](index=124&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to interest rate risk on **$360.0 million** variable-rate debt and foreign currency risk, with potential adverse impacts - The company is exposed to interest rate risk on approximately **$360.0 million** of its variable-rate debt, where a **1.0%** increase in interest rates would have an estimated adverse impact of **$0.7 million** on pre-tax earnings for the quarter[135](index=135&type=chunk)[136](index=136&type=chunk) - The company uses an interest rate swap to hedge **$200.0 million** of its variable-rate debt to manage risk[135](index=135&type=chunk) - The company is exposed to foreign currency exchange rate risk, primarily from Canadian and Australian Dollars, where a hypothetical **10%** adverse change in exchange rates would impact pre-tax income by approximately **$1.6 million** for the quarter[137](index=137&type=chunk)[138](index=138&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2021, with no material changes to internal controls - As of June 30, 2021, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[139](index=139&type=chunk) - No material changes to the company's internal control over financial reporting occurred during the quarter ended June 30, 2021[140](index=140&type=chunk) PART II. OTHER INFORMATION [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) No material changes occurred to the risk factors previously disclosed in the Annual Report on Form 10-K for the fiscal year ended March 31, 2021 - There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021[142](index=142&type=chunk) [Issuer Purchases of Equity Securities](index=35&type=section&id=Item%202.%20Issuer%20Purchases%20of%20Equity%20Securities) The company repurchased **63,314 shares** at **$46.04** per share to satisfy tax-withholding requirements for employee equity awards Issuer Purchases of Equity Securities (May 1 to May 31, 2021) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | May 1 to May 31, 2021 | 63,314 | $46.04 | - Share repurchases were conducted to satisfy tax-withholding requirements upon the vesting of shares under the 2005 Long-Term Equity Incentive Plan[144](index=144&type=chunk) [Other Information](index=35&type=section&id=Item%205.%20Other%20Information) The 2021 Annual Meeting of Stockholders elected directors, ratified auditors, and approved executive compensation on a non-binding basis - The 2021 Annual Meeting of Stockholders was held on August 3, 2021[145](index=145&type=chunk) - Stockholders voted on and approved three proposals: the election of seven directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and a non-binding resolution on executive compensation[145](index=145&type=chunk)[147](index=147&type=chunk)[148](index=148&type=chunk)[149](index=149&type=chunk) [Exhibits](index=37&type=section&id=Item%206.%20Exhibits) Key exhibits filed include the Asset Purchase Agreement with Akorn Operating Company and Amendment No. 6 to the Term Loan Credit Agreement - Key exhibits filed include the Asset Purchase Agreement with Akorn Operating Company and Amendment No. 6 to the Term Loan Credit Agreement[153](index=153&type=chunk)

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Philip Terpolilli - Vice President, Investor Relations and Treasury Ron Lombardi - Chairman, President and Chief Executive Officer Christine Sacco - Chief Financial Officer Conference Call Participants Erica Eiler - Oppenheimer Seb Barbero - Jefferies Linda Bolton-Weiser - D.A. Davidson Operator Good day and thank you for standing by. Welcome to the Q4 2021 Prestige Consumer Healthcare I ...

PLE CLEA 0 ULTIMATE HEALTHCARE Fourth Quarter & Full-Year FY 2021 Results May 6tʰ, 2021 Safe Harbor Disclosure 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, EPS, free cash flow, and organic revenue growth; the Company's ability to perform well in the currently evolving environment and execute on its brand-building strat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-1297589 (State ...